Curadigm

Curadigm is a nanotechnology company and a subsidiary of Nanobiotix SA, dedicated to improving treatment outcomes for millions of patients by redefining the therapeutic balance between bioavailability, toxicity, and efficacy. Curadigm, a spin-off from Nanobiotix, was incorporated in 2019 based on a proprietary platform aimed at reshaping and enhancing the efficacy of intravenously administered therapeutic agents.Curadigm’s technology focuses on engineered biocompatible nanoparticles that temporarily occupy pathways responsible for therapeutic clearance and hepatotoxicity. This results in enhanced systemic bioavailability and improved accumulation in target tissues. By mitigating toxicity while amplifying the beneficial aspects of therapeutic agents, this approach aims to improve patient quality of life, enhance outcomes, and reduce costs.Curadigm’s technology has broad applicability and can be adapted to various therapeutic categories, including nanomedicines, nucleic acid therapeutics, small molecules, and gene-editing technologies across multiple therapeutic areas.